| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
The primary target of ACT-335827 is the orexin type 1 receptor (OX1R). It is a selective antagonist with an IC₅₀ of 6 nM for OX1R and 417 nM for OX2R. Orexin, also known as hypocretin, is a neuropeptide that contributes to the expression of cardiovascular and behavioral responses to some forms of stress, including novelty stress. By selectively blocking the OX1 receptor, ACT-335827 can modulate orexin-mediated effects without significantly affecting OX2-mediated pathways.
|
|---|---|
| ln Vitro |
In CHO cells, ACT-335827 (0-10 μM, 2 h) acts on OXR-1 and OXR-2, with IC50 values of 2300 nM and 41 nM, respectively, and Kb values of 41 nM and 560 nM [1].
In vitro, ACT-335827 demonstrates potent and selective antagonism of the orexin OX1 receptor. Its binding affinity (Kb) for OX1 and OX2 receptors is 41 nM and 560 nM, respectively. The compound's IC₅₀ values for OX1 and OX2 are 6 nM and 417 nM, respectively. These in vitro data confirm its high selectivity for the OX1 receptor over the OX2 subtype. The compound's activity is characterized in standard radioligand binding and functional assays. |
| ln Vivo |
Rats' startle reactions can be lessened by ACT-335827 (oral gavage, 30-100 mg/kg once), without impairing their motor or cognitive abilities [1]. Diet-induced obesity (DIO) in male Wistar rats is one metabolic syndrome (MetS) condition that ACT-335827 (oral, 300 mg/kg, daily, 4 weeks) has less of an impact on [2].
In vivo, ACT-335827 elicits anxiolytic effects. As an orally active and brain-penetrant compound, it is used to study the role of the orexin system in stress and anxiety-related behaviors. In animal models, it has been shown to modulate the cardiovascular and behavioral responses to stress. These effects are attributed to its selective antagonism of the OX1 receptor, which is a key mediator of stress responses. |
| Enzyme Assay |
In vitro receptor binding studies for ACT-335827 measure its affinity for the orexin OX1 and OX2 receptors. Radioligand competition assays are performed using membrane preparations from cells expressing the human OX1 or OX2 receptors. The compound competes with a labeled orexin peptide for binding, and the IC₅₀ or Ki values are determined from the competition curves. Selectivity is assessed by comparing the compound's affinity for OX1 versus OX2 receptors.
|
| Cell Assay |
In vitro cell-based assays for ACT-335827 evaluate its functional antagonism at the orexin receptors. Cells expressing OX1 or OX2 receptors are treated with an orexin agonist in the presence or absence of ACT-335827. Receptor activation is measured by downstream signaling, such as intracellular calcium mobilization. The compound's ability to block the agonist-induced response is measured. Standard cell culture and signaling assays are used.
|
| Animal Protocol |
Animal/Disease Models: Rat[1]
Doses: 30, 100 or 300 mg/kg Route of Administration: po (oral gavage); Experimental Results: At the dose of 300 mg/kg, the startle response caused by fear was diminished. At 300 mg/kg, it can reduce the increase in body temperature caused by stress, and at 100 or 300 mg/kg, it can accelerate the fever rate, but has no effect on exercise and blood pressure. Animal/Disease Models: Male Wistar rat, weight 160-180g[2] Doses: 300mg/kg Route of Administration: po (po (oral gavage)) 200mg/kg. Daily; 4 weeks Experimental Results: diminished preference for high-fat/sweet diets but no effect on absolute energy intake. Water intake and HDL content increased relative to total cholesterol. Compared with the control group, body weight increased by 4%. In vivo animal studies for ACT-335827 are conducted to evaluate its anxiolytic effects. Rodents are treated with the compound via oral administration, and behavioral tests such as the elevated plus maze or open field test are performed to assess anxiety-like behavior. Physiological parameters such as heart rate and blood pressure are also measured. The compound's ability to block stress-induced responses is evaluated. All procedures must comply with institutional animal care guidelines. |
| ADME/Pharmacokinetics |
The pharmacokinetic properties of ACT-335827 are consistent with an orally bioavailable, brain-penetrant compound. Its molecular weight is 518.65 g/mol. The compound is formulated in DMSO for research use. It should be stored as a powder at -20°C for long-term stability. Further details on its PK profile are available from the primary research literature.
|
| Toxicity/Toxicokinetics |
The toxicity profile of ACT-335827 has not been extensively detailed in the available literature. It is classified for research use only and not for human consumption. As a potent and selective receptor antagonist, its safety profile would require further investigation in preclinical studies. Standard safety precautions for handling bioactive compounds should be followed.
|
| References |
|
| Additional Infomation |
Additional information: ACT-335827 has the CAS number 1354039-86-3. Its IUPAC name is (R)-2-((S)-1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-N-isopropyl-2-phenylacetamide. The compound is soluble in DMSO. It is intended for preclinical research use only and cannot be used to diagnose, treat or manage patients. This product is for research use only and is not approved for clinical or therapeutic applications.
|
| Molecular Formula |
C31H38N2O5
|
|---|---|
| Molecular Weight |
518.65
|
| Exact Mass |
518.278
|
| CAS # |
1354039-86-3
|
| PubChem CID |
54765113
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
5.457
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
38
|
| Complexity |
729
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC(C)NC(=O)[C@@H](C1=CC=CC=C1)N2CCC3=CC(=C(C=C3[C@@H]2CC4=CC(=C(C=C4)OC)OC)OC)OC
|
| InChi Key |
HXHOBPVRRPCTLG-SETSBSEESA-N
|
| InChi Code |
InChI=1S/C31H38N2O5/c1-20(2)32-31(34)30(22-10-8-7-9-11-22)33-15-14-23-18-28(37-5)29(38-6)19-24(23)25(33)16-21-12-13-26(35-3)27(17-21)36-4/h7-13,17-20,25,30H,14-16H2,1-6H3,(H,32,34)/t25-,30+/m0/s1
|
| Chemical Name |
(R)-2-((S)-1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-N-isopropyl-2-phenylacetamide
|
| Synonyms |
ACT-335827 ACT335827 ACT 335827
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9281 mL | 9.6404 mL | 19.2808 mL | |
| 5 mM | 0.3856 mL | 1.9281 mL | 3.8562 mL | |
| 10 mM | 0.1928 mL | 0.9640 mL | 1.9281 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
